CL2021001636A1 - Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar - Google Patents
Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonarInfo
- Publication number
- CL2021001636A1 CL2021001636A1 CL2021001636A CL2021001636A CL2021001636A1 CL 2021001636 A1 CL2021001636 A1 CL 2021001636A1 CL 2021001636 A CL2021001636 A CL 2021001636A CL 2021001636 A CL2021001636 A CL 2021001636A CL 2021001636 A1 CL2021001636 A1 CL 2021001636A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- pharmaceutical composition
- arterial hypertension
- pulmonary arterial
- aprocitentan
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 title 1
- DKULOVKANLVDEA-UHFFFAOYSA-N ACT-132577 Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)N)=NC=NC=1OCCOC1=NC=C(Br)C=N1 DKULOVKANLVDEA-UHFFFAOYSA-N 0.000 abstract 2
- 229940070148 aprocitentan Drugs 0.000 abstract 2
- JGCMEBMXRHSZKX-UHFFFAOYSA-N macitentan Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)NCCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 JGCMEBMXRHSZKX-UHFFFAOYSA-N 0.000 abstract 2
- 229960001039 macitentan Drugs 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 208000037849 arterial hypertension Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000000877 morphologic effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se relaciona con dosis elevadas de macitentán, o sales farmacéuticamente aceptables, solvatos, hidratos o formas morfológicas de este, o de aprocitentán, y una composición farmacéutica que los comprende, para uso en el tratamiento y/o prevención de la hipertensión arterial pulmonar (HAP), y para la elaboración de un medicamento. Describe también un régimen de dosificación para el mismo uso, así como una combinación de macitentán, o de aprocitentán, con otro agente activo.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2018086724 | 2018-12-21 | ||
| EP2019051830 | 2019-01-25 | ||
| EP2019060151 | 2019-04-18 | ||
| EP2019066494 | 2019-06-21 | ||
| EP2019067186 | 2019-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021001636A1 true CL2021001636A1 (es) | 2022-02-18 |
Family
ID=69147670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021001636A CL2021001636A1 (es) | 2018-12-21 | 2021-06-18 | Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US11234980B2 (es) |
| EP (1) | EP3897646B1 (es) |
| JP (2) | JP2022512493A (es) |
| KR (1) | KR20210109558A (es) |
| CN (1) | CN113194953A (es) |
| AU (1) | AU2019410727B2 (es) |
| BR (1) | BR112021011999A2 (es) |
| CA (1) | CA3123990A1 (es) |
| CL (1) | CL2021001636A1 (es) |
| CO (1) | CO2021007186A2 (es) |
| DK (1) | DK3897646T3 (es) |
| ES (1) | ES2983314T3 (es) |
| FI (1) | FI3897646T3 (es) |
| HR (1) | HRP20240875T1 (es) |
| HU (1) | HUE067126T2 (es) |
| IL (1) | IL284136A (es) |
| JO (1) | JOP20210153B1 (es) |
| LT (1) | LT3897646T (es) |
| MA (1) | MA54522B1 (es) |
| MX (1) | MX2021007455A (es) |
| PH (1) | PH12021551371A1 (es) |
| PL (1) | PL3897646T3 (es) |
| PT (1) | PT3897646T (es) |
| RS (1) | RS65689B1 (es) |
| SG (1) | SG11202105098VA (es) |
| SI (1) | SI3897646T1 (es) |
| SM (1) | SMT202400274T1 (es) |
| TW (1) | TWI841649B (es) |
| WO (1) | WO2020128017A1 (es) |
| ZA (1) | ZA202105111B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3658140B1 (en) | 2017-02-27 | 2025-05-21 | Idorsia Pharmaceuticals Ltd | Combinations of aprocitentan with further active ingredients for the treatment of resistant hypertension |
| CA3116166C (en) * | 2018-10-12 | 2026-02-17 | Sanotize Research And Development Corp. | Gas-evolving compositions and container and delivery systems |
| SMT202400274T1 (it) | 2018-12-21 | 2024-09-16 | Actelion Pharmaceuticals Ltd | Macitentan per il trattamento di ipertensione arteriosa polmonare |
| TW202042818A (zh) * | 2019-01-25 | 2020-12-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療慢性血栓性肺高血壓之醫藥組成物 |
| BR112022010311A2 (pt) * | 2019-11-29 | 2022-08-16 | Actelion Pharmaceuticals Ltd | Métodos de tratamento de hipertensão arterial pulmonar |
| CA3208560A1 (en) * | 2021-02-26 | 2022-09-01 | Mark Rocco | Methods for treating pulmonary hypertension in patients with left ventricular assist device implantation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002053557A1 (en) | 2000-12-18 | 2002-07-11 | Actelion Pharmaceuticals Ltd | Novel sulfamides and their use as endothelin receptor antagonists |
| WO2007031933A2 (en) | 2005-09-12 | 2007-03-22 | Actelion Pharmaceuticals Ltd | Stable pharmaceutical composition comprising a pyrimidine-sulfamide |
| AR062501A1 (es) | 2006-08-29 | 2008-11-12 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas |
| MX2010001837A (es) | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
| ES2763176T3 (es) | 2008-08-13 | 2020-05-27 | Actelion Pharmaceuticals Ltd | Composiciones terapéuticas que contienen macitentan |
| KR20230021186A (ko) | 2016-11-10 | 2023-02-13 | 아레나 파마슈티칼스, 인크. | 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법 |
| WO2018153925A1 (en) * | 2017-02-22 | 2018-08-30 | Amneal Pharmaceuticals Company Gmbh | Stable pharmaceutical compositions comprising macitentan |
| EP3658140B1 (en) * | 2017-02-27 | 2025-05-21 | Idorsia Pharmaceuticals Ltd | Combinations of aprocitentan with further active ingredients for the treatment of resistant hypertension |
| SMT202400274T1 (it) | 2018-12-21 | 2024-09-16 | Actelion Pharmaceuticals Ltd | Macitentan per il trattamento di ipertensione arteriosa polmonare |
| TW202042818A (zh) | 2019-01-25 | 2020-12-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療慢性血栓性肺高血壓之醫藥組成物 |
| TW202103703A (zh) | 2019-04-05 | 2021-02-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療門脈肺高血壓之方法 |
| CA3158468A1 (en) | 2019-11-26 | 2021-06-03 | Denes Csonka | Pharmaceutical composition for the treatment of pulmonary vascular disease and/or cardiac dysfunction in fontan-palliated patients |
-
2019
- 2019-12-20 SM SM20240274T patent/SMT202400274T1/it unknown
- 2019-12-20 HU HUE19832954A patent/HUE067126T2/hu unknown
- 2019-12-20 BR BR112021011999-0A patent/BR112021011999A2/pt unknown
- 2019-12-20 MX MX2021007455A patent/MX2021007455A/es unknown
- 2019-12-20 SI SI201930781T patent/SI3897646T1/sl unknown
- 2019-12-20 WO PCT/EP2019/086754 patent/WO2020128017A1/en not_active Ceased
- 2019-12-20 HR HRP20240875TT patent/HRP20240875T1/hr unknown
- 2019-12-20 KR KR1020217022508A patent/KR20210109558A/ko not_active Ceased
- 2019-12-20 PL PL19832954.2T patent/PL3897646T3/pl unknown
- 2019-12-20 EP EP19832954.2A patent/EP3897646B1/en active Active
- 2019-12-20 FI FIEP19832954.2T patent/FI3897646T3/fi active
- 2019-12-20 LT LTEPPCT/EP2019/086754T patent/LT3897646T/lt unknown
- 2019-12-20 ES ES19832954T patent/ES2983314T3/es active Active
- 2019-12-20 MA MA54522A patent/MA54522B1/fr unknown
- 2019-12-20 SG SG11202105098VA patent/SG11202105098VA/en unknown
- 2019-12-20 TW TW108146917A patent/TWI841649B/zh active
- 2019-12-20 CA CA3123990A patent/CA3123990A1/en active Pending
- 2019-12-20 CN CN201980084868.5A patent/CN113194953A/zh active Pending
- 2019-12-20 RS RS20240742A patent/RS65689B1/sr unknown
- 2019-12-20 AU AU2019410727A patent/AU2019410727B2/en active Active
- 2019-12-20 PT PT198329542T patent/PT3897646T/pt unknown
- 2019-12-20 DK DK19832954.2T patent/DK3897646T3/da active
- 2019-12-20 JP JP2021533836A patent/JP2022512493A/ja active Pending
-
2021
- 2021-03-02 US US17/189,881 patent/US11234980B2/en active Active
- 2021-05-31 CO CONC2021/0007186A patent/CO2021007186A2/es unknown
- 2021-06-10 PH PH12021551371A patent/PH12021551371A1/en unknown
- 2021-06-16 JO JOJO/P/2021/0153A patent/JOP20210153B1/ar active
- 2021-06-17 IL IL284136A patent/IL284136A/en unknown
- 2021-06-18 CL CL2021001636A patent/CL2021001636A1/es unknown
- 2021-07-20 ZA ZA2021/05111A patent/ZA202105111B/en unknown
- 2021-10-29 US US17/515,132 patent/US11464777B2/en active Active
-
2022
- 2022-09-27 US US17/953,530 patent/US20230020241A1/en not_active Abandoned
-
2024
- 2024-05-08 JP JP2024075949A patent/JP2024105450A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017012991A (es) | Combinaciones de amisulprida y otro antiemetico para tratar nausea y vomito. | |
| ECSP22023220A (es) | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| CO2021007186A2 (es) | Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar | |
| MX2019001850A (es) | Formulaciones para administracion oral de principios activos. | |
| CL2018003390A1 (es) | Beta-horquilla peptidomimética con actividad inhibidora de elastasa y formas de dosificación en aerosol de la misma. | |
| MX2018006799A (es) | Composicion farmaceutica. | |
| ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| CL2021002107A1 (es) | Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria. | |
| MX2018001989A (es) | Formulaciones farmaceuticas. | |
| AR112282A1 (es) | Uso de la combinación de cabotegravir y rilpivirina para preparar una forma farmacéutica | |
| MX2016014256A (es) | Formulaciones y metodos para el suministro vaginal de antiprogestinas. | |
| ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| CO2021011046A2 (es) | Composición farmacéutica que comprende macitentán para el tratamiento de la hipertensión pulmonar tromboembólica crónica | |
| CL2014003326A1 (es) | Formulación antioxidante inyectable de uso intravenoso de ascorbato de sodio - en altas dosis, y n-acetilcisteína como agentes oxidantes, y deferoxamina como agentes quelante de hierro, más excipientes farmacéuticos; método para su administración y uso en prevenir el daño por repertfusión en pacientes con inferto agudo del miocardío, sometidos a angioplastia caronaria primaria; y kit que la contiene. | |
| CO2020000292A2 (es) | Preparación medicinal combinada para tratar infecciones virales | |
| CL2018003707A1 (es) | Regímenes de dosificación de vortioxetina para el rápido inicio del efecto antidepresivo. | |
| DOP2022000004A (es) | Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad | |
| AR105087A1 (es) | Métodos para el tratamiento de mujeres con trastorno de deseo sexual hipoactivo (hsdd) con el tratamiento de combinación bupropión y trazodona | |
| MX2020004403A (es) | Composiciones farmaceuticas que comprenden safinamida. | |
| AR108793A1 (es) | Composiciones que comprenden timolol y un agente antiinflamatorio | |
| CO2017000354A2 (es) | Desmopresina estabilizada | |
| CO2019013645A2 (es) | Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas | |
| AR115293A1 (es) | Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar | |
| AR099330A1 (es) | Uso de paricalcitol en el tratamiento de la anemia inflamatoria |